Biotest AG / Key word(s): Corporate Action 17.03.2015 15:45 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- / Ad-hoc RELEASE Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting - Proposed capital increase without issuing new shares - Proposed share split with the relation of one to three Dreieich, 17 March 2015. Biotest AG will propose a capital increase from capital funds and a share split with the relation of one to three by means of a reclassification of the share capital to its Annual General Meeting on 7 May 2015. Biotest share prices have increased significantly in recent years. The proposed share split is intended to promote the liquidity and accessibility of the Biotest shares and to make the Biotest shares even more attractive also for a broader group of investors. The share capital of Biotest AG currently amounts to EUR 33,767,639.04 and is divided into 6,595,242 ordinary shares and into 6,595,242 preference shares without voting rights. Thus, one ordinary or preference share has a proportional amount of the share capital of EUR 2.56. After the implementation of the capital increase from capital funds by EUR 5,803,812.96 to EUR 39,571,452.00 without issuing new shares and the share split, each current holder of one existing ordinary or preference share would hold in future three ordinary or preference shares with a proportional amount of the share capital of EUR 1.00. The agenda of the Annual General Meeting resolved today by the Supervisory Board and the Management Board will be published presumably on 25 March 2015. In accordance with the proposed share split, Biotest also proposed several amendments to the articles of association, e.g. appropriation of profit and the remuneration of the Supervisory Board. Biotest Aktiengesellschaft Board of Management Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.de Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2,100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 Securities' ID No., ISIN preference shares: 522723, DE0005227235 Listing: Prime Standard Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart 17.03.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Biotest AG LandsteinerstraÃe 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting
| Source: EQS Group AG